Cargando…
Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial
BACKGROUND: MeRes100™ (Meril Life Sciences Pvt. Ltd., Vapi, India) is a novel sirolimus-eluting bioresorbable vascular scaffold (BRS). The purpose of this sub-study of MeRes-1 trial is to evaluate the systemic release of sirolimus from MeRes100 BRS implanted for the treatment of de novo native coron...
Autores principales: | Chandra, Praveen, Mahajan, Ajaykumar U., Bulani, Vipin D., Thakkar, Ashok S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306117/ https://www.ncbi.nlm.nih.gov/pubmed/30627287 http://dx.doi.org/10.14740/cr799 |
Ejemplares similares
-
First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China
por: Chen, Jia-Hui, et al.
Publicado: (2015) -
Coronary Computed Tomography Angiography for the Assessment of Sirolimus-Eluting Resorbable Magnesium Scaffold
por: Tonet, Elisabetta, et al.
Publicado: (2022) -
Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer
por: Yang, Hyoung-Mo, et al.
Publicado: (2017) -
Final report of the 5-year clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in the treatment of single de novo coronary lesions in a first-in-human study
por: Wu, Yizhe, et al.
Publicado: (2020) -
Safe and effective profile of the VSTENT bioresorbable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions: a prospective, cohort, multicenter study
por: Tran, Hoa, et al.
Publicado: (2023)